Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abdominal, abnormal, acute, advice, AEs, AG, aggravated, anorexia, antihypertensive, appeal, arbitration, arm, article, assumption, atrial, attention, awaiting, bacteremia, bacteria, baseline, befall, belief, Benchmark, body, broader, Cantor, carcinoid, cardiac, cardiovascular, categorized, catheter, chest, circulating, cited, cohort, coli, commentary, commonly, compassionate, competitor, complaining, complaint, confusion, contest, contesting, convene, convened, convening, convertible, correlate, CRL, CRSP, CTC, CV, death, deep, dehydration, dichloride, died, dismissing, displayed, dosimetry, doubtful, durable, dyspnea, ECG, embolism, endpoint, EPLND, estate, exhausted, fatigue, febrile, ferrante, fever, fibrillation, finite, Fitzgerald, formal, frequent, Fuji, gland, headache, hearing, hematologic, hematuria, heretofore, Highland, hospitalized, hypoxia, ICB, Inborn, indefinite, infarction, INR, intangible, intubated, Journal, karen, kishbauch, kit, lab, laxated, leukopenia, leverage, lived, MACE, magnitude, mCRPC, Memorial, merit, mg, michael, mild, motion, MRI, muscle, myelodysplastic, myocardial, naive, Naldemedine, Naloxegol, nausea, neuroendocrine, neuropathy, neutropenia, neutropenic, Nuclear, OfferingSM, OMX, Onalta, Orange, outlicensed, overallotment, pancreatic, PFO, pneumonia, policing, postponed, proceeding, proportion, Protocol, protracted, published, pulmonary, quantitative, radiolabeled, radiopharmaceutical, rash, reaction, reassessed, RECIST, refractory, renal, replacement, replacing, resolved, respiratory, resuming, revealed, revert, RFBM, RP, Scherrer, septic, Shionogi, shock, simplified, site, SPA, statistically, Strep, subcontracting, Subsector, substitute, succeeding, suggested, superseded, suspected, tablet, tabular, tachycardia, Tangible, Tasmania, thereto, TR, trofolastat, tunnel, uncollectable, uncontrolled, underwriter, unilaterally, vein, ventilator, vigorously, vomiting, week, weekly, Xofigo, Zurich
Removed:
AHP, barrier, began, binding, briner, budgetary, capacity, carryback, cell, cliff, collected, concentrated, consultation, Deposit, earning, ending, goff, guaranteed, half, HIV, internalizing, kurt, neovasculature, occupy, pen, perpetual, Pfizer, phosphoinositide, Plant, predominantly, qualifying, recovered, refund, registering, repurchase, sector, solid, source, spend, stephen, studied, surface, undergoing, undiscounted, Union, unresolved, updated
Filing tables
Filing exhibits
- 10-K Annual report
- 12.1 Exhibit 12.1 Ratio
- 21.1 Exhibit 21.1 Subsidiaries of Progenics Pharmaceuticals, Inc.
- 23.1 Exhibit 23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 Exhibit 23.2 Consent of Ernst & Young LLP
- 31.1 Exhibit 31.1 Certification
- 31.2 Exhibit 31.2 Certification
- 32.1 Exhibit 32.1 Certification
- 32.2 Exhibit 32.2 Certification
- 10.40 Exhibit 10.40
- Download Excel data file
- View Excel data file
Related press release
PGNX similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-193521) including the related Prospectus and Prospectus Supplement; |
(2) | Registration Statements (Form S-8 Nos. 333-183511, 333-124910, 333-143670, 333-160389, and 333-176204) pertaining to the 2005 Stock Incentive Plan; |
(3) | Registration Statements (Form S-8 Nos. 333-52277 and 333-120508) pertaining to its Amended and Restated1996 Stock Incentive Plan; |
of our reports dated March 13, 2014, with respect to the consolidated financial statements and schedule of Progenics Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of Progenics Pharmaceuticals, Inc., included in the Company's Annual Report (Form 10-K) for the year ended December 31, 2013.
/s/ Ernst & Young LLP
Hartford, Connecticut
March 13, 2014